S
Description
Selvita S.A., founded in 2007 in Kraków and listed on the Warsaw Stock Exchange, is a leading global CRO in drug discovery and development with 900+ specialists across 6 sites in 4 countries (Poland, Croatia; US and UK offices). Services span drug discovery, drug development and contract testing under GMP and GLP standards. Key acquisitions: BioCentrum (2008), Fidelta/Croatia (2021), PozLab (2024). Leading European integrated CRO.